Proprietary Chinese medicine for treating cancer of the lungs and method of preparing the same

Abstract

The invention relates to a Chinese preparation for treating lung carcinoma and process for preparation, wherein the constituents of the raw material include (by weight percent) prepared fleece-flower root 12-19%, notoginseng 4-9%, flitilarry bulb 5-8%, pericarpium trichosanthis 6-9%, peach kernel 4-9%, ground beetle 5-9%, red ginseng 6-9%, dyers woad leaf 7-15%, subprostrate sophora root 6-9%, poria cocos wolf 6-9%, lepidium seed 6-9%, dried orange peel 6-9%. The dose form of the medicament can be oral liquids, granules, capsules, powders, pills or tablets.

Description

technical field [0001] The invention relates to a Chinese patent medicine and a preparation method thereof, in particular to a Chinese patent medicine for treating lung cancer and a preparation method thereof. Background technique [0002] Primary bronchial lung cancer (IBS) is one of the most common malignant tumors. At present, it is believed that the main reasons for the prevalence of lung cancer are smoking and air pollution, and it is predicted that lung cancer will increase significantly in the next few years. Only 10-20% of lung cancer patients can be surgically resected in the early stage, and about 80-90% of lung cancer patients are already at an advanced stage when they are diagnosed. They lose the opportunity for surgical treatment and cannot bear the pain of chemotherapy. So far, there is no better solution for the treatment of lung cancer. Like other malignant tumors, the etiology, pathogenesis, diagnosis and treatment of lung cancer are quite complicated. 60...

AI Technical Summary

Problems solved by technology

Like other malignant tumors, the etiology, pathogenesis, diagnosis and treatment of lung cancer are quite complicated. 60 The rapid development of , fast neutron, laser and immunotherapy has improved the clinical curative effect to varying degrees, but with the progress of basic medical research, many data show that patients often have micrometastases at the time of diagnosis, so-called "early" cancer In fact, 2 / 3 of the cases have already had cancer metastasis at the time of first diagnosis, and more than 50 effective drugs have been found, but most of them inhibit the DNA biosynthesis of cancer cells to exert their therapeutic effect, and they do not have the ability to selectively kill tumor cells Specific, vigorously proliferating normal cells, such as bone marrow hematopoietic cells, gastrointestinal mucosal cells, germ cells, and hair follicle epithelial cells, are also inevitably inhibited, resulting in varying degrees of toxic reactions and complications in clinical practice